Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Part of paid clinical trials in Oakland, California.

Sponsor
Pharmacosmos A/S
Study ID
NCT07473128
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Limited Stage Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trilaciclib — DRUG
    Intravenous infusion
  • Saline (0.9% NaCl) — DRUG
    Intravenous infusion

Study Details

The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.

Key Dates

Start date
Jun 30, 2026
Status verified
Jun 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Trilaciclib
    Receives trilaciclib
  • Placebo Comparator: Placebo
    Receives placebo

Primary Outcome Measure

To Compare trilaciclib to placebo on prevention of myelosuppression [ Time Frame: From enrollment and 4 months after ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Pharmacosmos Investigational SiteOaklandCalifornia48073
Pharmacosmos A/S Clinical and non-clinical research
[email protected]
455-948-5959

Find similar trials in Oakland, CA

By research site
Pharmacosmos Investigational Site· Oakland, CA

Related Studies